TY - JOUR
T1 - Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample
AU - King, Darlene R.
AU - Salako, Damilola C.
AU - Arthur-Bentil, Samia Kate
AU - Rubin, Arielle E.
AU - Italiya, Jay B.
AU - Tan, Jenny S.
AU - Macris, Dimitri G.
AU - Neely, Hunter K.
AU - Palka, Jayme M.
AU - Grodin, Justin L.
AU - Davis-Bordovsky, Kaylee
AU - Faubion, Matthew
AU - North, Carol S.
AU - Brown, E. Sherwood
N1 - Publisher Copyright:
© 2020
PY - 2021/2/15
Y1 - 2021/2/15
N2 - Major depressive disorder is associated with pro-inflammatory markers, such as cytokines TNF-alpha, IL-6, IL-1ß, and C-reactive protein. Galectin-3 is a novel emerging biomarker with pro-inflammatory properties. It is a saccharide binding protein distributed throughout many tissues with varying functions and is a predictor of poor outcomes in patients with heart failure and stroke. However, its role as a predictor in depressive symptom severity remains undefined. Data from the community-based Dallas Heart Study (n = 2554) were examined using a multiple linear regression analysis to evaluate the relationship between galectin-3 and depressive symptom severity as assessed with Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) scores. Additional covariates included age, sex, race/ethnicity, body mass index (BMI), years of education, serum creatinine, history of diabetes, and smoking history. Galectin-3 levels statistically significantly predicted QIDS-SR depressive symptom severity (β = 0.055, p =.015). Female sex, smoking status, and BMI were found to be statistically significant positive predictors of depression severity, while age, years of education, non-Hispanic White race, and Hispanic ethnicity were negative predictors of depressive symptom severity. In this large sample, higher galectin-3 levels were associated with higher levels of depressive symptoms. The findings suggest that galectin-3 may be a new and useful inflammatory biomarker associated with depression.
AB - Major depressive disorder is associated with pro-inflammatory markers, such as cytokines TNF-alpha, IL-6, IL-1ß, and C-reactive protein. Galectin-3 is a novel emerging biomarker with pro-inflammatory properties. It is a saccharide binding protein distributed throughout many tissues with varying functions and is a predictor of poor outcomes in patients with heart failure and stroke. However, its role as a predictor in depressive symptom severity remains undefined. Data from the community-based Dallas Heart Study (n = 2554) were examined using a multiple linear regression analysis to evaluate the relationship between galectin-3 and depressive symptom severity as assessed with Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) scores. Additional covariates included age, sex, race/ethnicity, body mass index (BMI), years of education, serum creatinine, history of diabetes, and smoking history. Galectin-3 levels statistically significantly predicted QIDS-SR depressive symptom severity (β = 0.055, p =.015). Female sex, smoking status, and BMI were found to be statistically significant positive predictors of depression severity, while age, years of education, non-Hispanic White race, and Hispanic ethnicity were negative predictors of depressive symptom severity. In this large sample, higher galectin-3 levels were associated with higher levels of depressive symptoms. The findings suggest that galectin-3 may be a new and useful inflammatory biomarker associated with depression.
KW - Dallas Heart Study
KW - Galectin-3
KW - Inflammation
KW - Major Depressive Disorder
KW - QIDS-SR
UR - http://www.scopus.com/inward/record.url?scp=85097881635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097881635&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2020.12.050
DO - 10.1016/j.jad.2020.12.050
M3 - Article
C2 - 33352408
AN - SCOPUS:85097881635
SN - 0165-0327
VL - 281
SP - 384
EP - 389
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -